Skepplanda (SE)
{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~28 mi. (Göteborg, Sweden, +144 more cities)
facility
Sahlgrenska Universitetssjukhuset ( Site 2102)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~28 mi. (Göteborg, Sweden, +199 more cities)
facility
Sahlgrenska Universitetssjukhuset ( Site 0691)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~36 mi. (Uddevalla, Sweden, +156 more cities)
facility
Uddevalla sjukhus /ID# 201315
biomarker
IGH-CCND1 Fusion, +1 more biomarker
condition
Multiple Myeloma
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~98 mi. (Jönköping, Sweden, +159 more cities)
facility
Laenssjukhuset Ryhov ( Site 1205)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type